Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

Leukemia. 2015 Dec;29(12):2402-4. doi: 10.1038/leu.2015.245. Epub 2015 Sep 15.

¹ Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
² Novartis Pharma GmbH, Nürnberg, Germany.
³ Department of Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany.
⁴ Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA.
⁵ Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany.
⁶ Department of Hematology/Oncology, Universitätsmedizin Mannheim, Germany.
⁷ Institute for Occupational and Social Medicine, Aachen University, Aachen, Germany.

No abstract available

Publication types